Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Fineline Cube Apr 28, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Deals

Genesis Healthcare & MGI Sign Strategic MOU to Accelerate Precision Medicine in Japan

Fineline Cube Oct 16, 2025

Genesis Healthcare, a leading Japanese genetic‑testing provider, today announced the signing of a Memorandum of...

Company Deals

Nuance Pharma Partners with Stallergenes Greer to Launch Actair in China

Fineline Cube Oct 15, 2025

Nuance Pharma, an innovation-focused biopharmaceutical company, and Stallergenes Greer, a global leader in the allergy...

Policy / Regulatory

Pfizer CEO Bourla Highlights Benefits of China Biotech Collaborations at NY Gala

Fineline Cube Oct 15, 2025

Albert Bourla, CEO of Pfizer Inc. (NYSE: PFE), highlighted the benefits of collaborations between multinational...

Company Deals

Uni-Bio Science Partners with Sinovac to Expand Teriparatide Injection Globally

Fineline Cube Oct 15, 2025

Uni-Bio Science Group Limited (HKG: 0690), a China-based company, announced on September 12, 2025, that...

Company Deals

Adagene Expands Exelixis Collaboration to Include Third Target Using SAFEbody Technology

Fineline Cube Oct 15, 2025

Adagene Inc. (NASDAQ: ADAG) announced on September 16, 2025, that its collaboration and license agreement...

Company Deals

Ollin Biosciences Launches With $100M Funding to Advance Ophthalmology Pipeline

Fineline Cube Oct 15, 2025

Ollin Biosciences, Inc. (Ollin), a clinical-stage biopharmaceutical company, announced its launch on September 16, 2025,...

Company Deals

Yanyin Tech and CirCode Biomed Forge Three-Year RNA Drug Development Partnership

Fineline Cube Oct 15, 2025

Yanyin Tech and Shanghai CirCode Biomed Co. Ltd. have announced a three-year strategic cooperation agreement...

Company Deals

China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases

Fineline Cube Oct 15, 2025

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) and Suzhou Rigerna Therapeutics have entered into...

Company Deals

Livzon Launches China’s First Oral GnRH Antagonist for Multiple Indications

Fineline Cube Oct 15, 2025

Livzon Pharmaceutical Group Inc. (HKG: 1513), a China-based company, announced on September 10, 2025, the...

Company Deals

Pacific Shuanglin’s Controlling Stake Transferred to CNBG in RMB 4.7B Deal

Fineline Cube Oct 15, 2025

Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE: 000403), a China-based blood products company, announced that its...

Company Deals

Jingze Bio and CMS Subsidiary Partner to Commercialize Key Products in Reproduction and Ophthalmology

Fineline Cube Oct 15, 2025

On September 12, 2025, Jingze Biopharmaceutical (Hefei) Co., Ltd., based in China, and a subsidiary...

Company Deals

Yanyin Tech and ChangJiang Pharma Partner to Advance AI in Drug Development

Fineline Cube Oct 15, 2025

China-based Yanyin Tech and YiChang HEC ChangJiang Pharmaceutical Co., Ltd. announced on September 12, 2025,...

Drug

Sino Biopharmaceutical’s Partner CTTQ Secures Breakthrough Therapy Designation for TQ‑B3234 Capsule in China

Fineline Cube Oct 15, 2025

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of China‑based Sino Biopharmaceutical Ltd. (HKG: 1177), today...

Company Drug

Pfizer Reports Positive Phase 3 HER2CLIMB‑05 Results for TUKYSA (Tucatinib) in First‑Line HER2+ MBC

Fineline Cube Oct 15, 2025

Pfizer Inc. (NYSE: PFE) today announced compelling topline results from the Phase 3 HER2CLIMB‑05 trial, evaluating...

Company Deals

Zennova & Rapafusyn Forge Alliance to Accelerate Non‑Degrading Molecular Glue Therapies

Fineline Cube Oct 15, 2025

Zennova Pharmaceutical announced today a strategic partnership with U.S.‑based biotech Rapafusyn Pharmaceuticals to jointly develop...

Company Deals Drug

Shenzhen Kangtai Secures 530 Million Yuan Technology Transfer for Klebsiella Pneumoniae Vaccine

Fineline Cube Oct 15, 2025

Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) today announced the signing of a technology‑transfer...

Company Drug

Eisai & Biogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer’s Disease

Fineline Cube Oct 15, 2025

Japanese pharmaceutical giant Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB)...

Company Deals

GenScript’s ProBio Secures RMB 479.7 M License Payment for LM‑299, Boosting SinoBiopharmaceutical’s Portfolio

Fineline Cube Oct 15, 2025

GenScript Biotech Corporation (HKG: 1548) today announced that its Contract‑Development‑and‑Manufacturing‑Organization (CDMO) platform, ProBio, received a...

Company Deals Drug

Chengdu Olymvax Biopharmaceuticals & Delonix Bioworks Announce Joint Development of Gene‑Engineered Pertussis Vaccine

Fineline Cube Oct 15, 2025

Chengdu Olymvax Biopharmaceuticals Inc. and Delonix Bioworks Co., Ltd. today announced a strategic collaboration and...

Company Deals Drug

Jiudian Pharma Acquires Chengdu Peide’s JIJ02 Gel, Advancing a Novel Acne Treatment into Phase 1

Fineline Cube Oct 15, 2025

Hunan Jiudian Pharmaceutical Co., Ltd. (SHE: 300705) today announced the acquisition of all developed results...

Posts pagination

1 … 85 86 87 … 658

Recent updates

  • Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization
  • Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
  • Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms
  • Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design
  • BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Others

Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms

Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.